Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 14 | 2023 | 291 | 3.000 |
Why?
|
| Candida | 9 | 2023 | 74 | 2.270 |
Why?
|
| Candidemia | 7 | 2023 | 40 | 2.240 |
Why?
|
| Echinocandins | 9 | 2023 | 44 | 2.100 |
Why?
|
| Candida glabrata | 4 | 2022 | 19 | 1.710 |
Why?
|
| Candidiasis | 7 | 2022 | 128 | 1.620 |
Why?
|
| Drug Resistance, Fungal | 3 | 2022 | 25 | 1.270 |
Why?
|
| Fungal Proteins | 3 | 2022 | 134 | 0.720 |
Why?
|
| Lipopeptides | 3 | 2023 | 33 | 0.650 |
Why?
|
| Microbiological Techniques | 1 | 2018 | 31 | 0.590 |
Why?
|
| Microbial Sensitivity Tests | 9 | 2019 | 791 | 0.590 |
Why?
|
| Blood | 1 | 2018 | 100 | 0.580 |
Why?
|
| Vancomycin | 4 | 2022 | 216 | 0.520 |
Why?
|
| Voriconazole | 1 | 2015 | 34 | 0.480 |
Why?
|
| Amphotericin B | 1 | 2012 | 90 | 0.390 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 295 | 0.390 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 100 | 0.370 |
Why?
|
| Candidiasis, Invasive | 2 | 2022 | 19 | 0.310 |
Why?
|
| beta-Lactams | 2 | 2019 | 51 | 0.290 |
Why?
|
| Mutation | 3 | 2015 | 5906 | 0.260 |
Why?
|
| Bacteremia | 2 | 2019 | 400 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 2371 | 0.220 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 561 | 0.210 |
Why?
|
| Moths | 1 | 2022 | 22 | 0.190 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 2055 | 0.180 |
Why?
|
| Anti-Infective Agents | 2 | 2013 | 257 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2018 | 116 | 0.160 |
Why?
|
| Azoles | 1 | 2019 | 8 | 0.160 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2019 | 220 | 0.160 |
Why?
|
| Fungi | 1 | 2019 | 69 | 0.150 |
Why?
|
| Humans | 21 | 2023 | 125110 | 0.150 |
Why?
|
| Bacterial Load | 1 | 2018 | 29 | 0.150 |
Why?
|
| Triazoles | 1 | 2019 | 140 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2022 | 492 | 0.150 |
Why?
|
| Mycoses | 1 | 2019 | 118 | 0.150 |
Why?
|
| Ceftriaxone | 1 | 2018 | 67 | 0.140 |
Why?
|
| Asymptomatic Infections | 1 | 2017 | 25 | 0.140 |
Why?
|
| Peritonitis | 1 | 2018 | 78 | 0.140 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 6537 | 0.140 |
Why?
|
| Inappropriate Prescribing | 1 | 2017 | 35 | 0.140 |
Why?
|
| Medical Overuse | 1 | 2017 | 24 | 0.140 |
Why?
|
| Fluconazole | 1 | 2017 | 48 | 0.140 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 66 | 0.130 |
Why?
|
| beta-Glucans | 1 | 2015 | 17 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2018 | 304 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 698 | 0.120 |
Why?
|
| Bacteria | 1 | 2018 | 477 | 0.110 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 237 | 0.110 |
Why?
|
| Middle Aged | 9 | 2019 | 26676 | 0.110 |
Why?
|
| Colony Count, Microbial | 1 | 2013 | 85 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 92 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2019 | 12272 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2014 | 335 | 0.100 |
Why?
|
| Metronidazole | 1 | 2013 | 154 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2015 | 372 | 0.100 |
Why?
|
| Glucosyltransferases | 1 | 2012 | 49 | 0.100 |
Why?
|
| Aged | 7 | 2018 | 19656 | 0.090 |
Why?
|
| Communicable Diseases | 1 | 2012 | 160 | 0.080 |
Why?
|
| Cell Line | 1 | 2015 | 2756 | 0.080 |
Why?
|
| Clostridium Infections | 1 | 2013 | 244 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 196 | 0.080 |
Why?
|
| Animals | 3 | 2022 | 34304 | 0.080 |
Why?
|
| Male | 10 | 2019 | 61443 | 0.080 |
Why?
|
| Time Factors | 1 | 2018 | 6302 | 0.070 |
Why?
|
| Tertiary Care Centers | 2 | 2018 | 237 | 0.060 |
Why?
|
| Female | 9 | 2019 | 66704 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 2906 | 0.060 |
Why?
|
| Prognosis | 1 | 2014 | 4683 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 1158 | 0.060 |
Why?
|
| Adult | 4 | 2018 | 29459 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2022 | 343 | 0.050 |
Why?
|
| Young Adult | 1 | 2014 | 9056 | 0.040 |
Why?
|
| Risk Factors | 1 | 2014 | 10278 | 0.040 |
Why?
|
| Candida albicans | 1 | 2019 | 76 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 87 | 0.040 |
Why?
|
| Virulence | 1 | 2019 | 265 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 551 | 0.040 |
Why?
|
| Mice | 1 | 2015 | 17740 | 0.040 |
Why?
|
| Clinical Audit | 1 | 2018 | 5 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2019 | 312 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 143 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 4821 | 0.030 |
Why?
|
| Hospitalization | 2 | 2015 | 1784 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2019 | 16339 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1242 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 358 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2878 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 391 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2015 | 55 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 772 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 308 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2013 | 52 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1800 | 0.030 |
Why?
|
| Peer Review | 1 | 2012 | 39 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 759 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 649 | 0.020 |
Why?
|
| Prevalence | 1 | 2018 | 2458 | 0.020 |
Why?
|
| Cross Infection | 1 | 2014 | 313 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3310 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 235 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2014 | 493 | 0.020 |
Why?
|
| Critical Illness | 1 | 2014 | 599 | 0.020 |
Why?
|
| Critical Care | 1 | 2014 | 656 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 1306 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4408 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 729 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 3402 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1265 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 6123 | 0.010 |
Why?
|
| United States | 1 | 2018 | 10884 | 0.010 |
Why?
|
| HIV Infections | 1 | 2012 | 1896 | 0.010 |
Why?
|